Skip to content
Menu

Revelation Biosciences Plans Accelerate Development Of Its Therapeutic Candidate Gemini; New Streamlined Phase 2a Study In Acute Kidney Injury To Deliver Topline Data In 2027 At Nearly 90% Lower Costs

Benzinga Newsdesk 23 hours ago

News

The strategy includes advancing a streamlined Phase 2a clinical study in patients with stage 2 or 3 acute kidney injury (AKI) to generate safety and efficacy data more rapidly and at substantially lower cost, while pursuing strategic partnerships and licensing opportunities to support Gemini’s development and expand its commercial potential.

AKI affects approximately 50% of intensive care unit patients and can lead to kidney failure and death. Dialysis remains a principal treatment for severe AKI, with mortality exceeding 50% in certain critically ill populations. Despite this substantial disease burden, no approved pharmacologic therapy directly addresses the underlying inflammatory processes contributing to kidney injury. Independent market research estimates approximately 2.3 million U.S. patients develop stage 2 or stage 3 AKI annually, representing a $94 billion total addressable market.

Gemini’s Differentiated Approach

Gemini is designed to restore balance to the body’s inflammatory response rather than broadly suppressing inflammation. By activating the TRIF signaling pathway and modulating multiple inflammatory actions, Gemini seeks to interrupt the cycle of inflammation and tissue damage, potentially improving kidney function and recovery.

Preclinical studies have demonstrated reduced inflammation and kidney tissue damage, while Phase 1 clinical studies established biological activity and favorable tolerability. In patients with chronic kidney disease, Gemini significantly reduced inflammatory activity and improved immune responsiveness, with effects observed for up to seven days.

Accelerated Phase 2a Development

Revelation plans to initiate a randomized, double-blind (sponsor-unblinded), placebo-controlled Phase 2a study in patients with stage 2 or stage 3 AKI in early 2027, with topline data anticipated in late 2027. The study will investigate safety and efficacy, including exploring approvable endpoints previously discussed with the FDA.

Led by Laurence Busse, MD, at Emory Healthcare, the largest and most comprehensive academic health system in the state of Georgia, with participation from Javier Neyra, MD, at the University of Alabama at Birmingham, widely ranked among top-tier U.S. biomedical and research institutions, the study is expected to cost approximately $7 million, compared with approximately $60 million under the Company’s previous development approach. Results are intended to inform subsequent clinical development and potentially strengthen Gemini’s position in pharmaceutical partnership discussions.

Strategic Partnership Opportunities

In parallel, Revelation intends to engage a business development firm to explore licensing agreements, development partnerships, and other strategic transactions with biotechnology and pharmaceutical companies. The Company believes Gemini’s differentiated, multimodal mechanism of action, encouraging early clinical data, and significant commercial opportunity in AKI positions it as an attractive candidate for potential strategic partners seeking innovative therapies targeting inflammation.

Beyond AKI, Gemini’s ability to regulate multiple inflammatory pathways offers potential applications across a broad range of acute and chronic diseases, including chronic kidney disease. This platform potential could provide additional opportunities for partnerships across multiple therapeutic areas. Revelation will also evaluate opportunities to acquire or in-license complementary therapeutic assets aligned with its focus on restoring inflammatory balance.

As of September 30, 2026, Revelation had $9.1 million in cash and cash equivalents.

Read at benzinga.com